In COVID-19 clinical update #54, Daniel Griffin covers effectiveness of 3 vs 6 ft physical distancing, effectiveness of masks, physical distancing, and eye shields, second vaccine dose completion, alleviation of COVID-19 symptoms after vaccination, vaccine trials in children, and IDSA approval of a mAb cocktail.
Forest and Maria-Isabel join TWiV to discuss their their project to engage thousands of citizens to swab inanimate surfaces in the San Diego area, then send the samples to the Rohwer Lab for nucleic acid analysis.
On a TWiV tetramer, we review the ongoing outbreaks of Ebolavirus disease in DRC and Guinea, evidence that SARS-CoV-2 infections in children are far more prevalent than are being detected, and recent long COVID estimates from the UK.
In COVID-19 clinical update #53, Daniel Griffin reviews underreporting of infections and long term disease in children, a blood test for T cells, results of phase 3 trials for monoclonal antibodies, preliminary findings on an oral antiviral, clinical trial of ivermectin, and recommendations for upcoming gatherings.
Matt Frieman returns to TWiV to discuss the COVID-19 pandemic from the point of view of a coronavirologist, including his work with Novavax on their spike protein-based vaccine.
In COVID-19 clinical update #52, Daniel Griffin reviews differences in attack rates between children and adults, J&J vaccine phase III data, G6PD deficiency and vaccines, NIH halts convalescent plasma trial, dexamethasone in hospitalized patients, data on tocilizumab, and long COVID in children.
Eva Harris and Janet Smith join TWiV to discuss how an antibody against dengue virus NS1 protein blocks endothelial dysfunction and the potential of treating infections by multiple flaviviruses.
Theodora and Paul return to TWiV to explain how they quickly pivoted their retrovirus laboratories towards SARS-CoV-2, their work on the antibody response to infection and its durability, and the emergence of variants with increased resistance to neutralization.
In COVID-19 clinical update #47, Daniel Griffin reviews phase 3 results for Novavax and J&J vaccines, transmission in K-12 settings in Wisconsin, data on Lilly and Regeneron monoclonal antibody therapy, and a study of colchicine for treatment of disease.
In Daniel Griffin’s final clinical report for 2020, he summarizes what we have learned about the clinical management of COVID-19 patients in the past year.